Application of vitepofen in preparation of medicine for treating psoriasis
By using vetepofen to inhibit keratinocyte proliferation and psoriasis-related inflammatory factors, the problem of lack of effective treatment of psoriasis in the prior art is solved, and effective treatment of psoriasis is achieved.
Patent Information
- Application Number
- CN202411041931.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective methods for treating psoriasis, and psoriasis has a long course and is prone to recurrence, making it difficult to cure it.
Vitepofen and its pharmaceutically acceptable salts are used to prepare drugs for treating psoriasis by inhibiting keratinocyte proliferation and the expression of psoriasis-related inflammatory factors.
Significantly inhibiting keratinocyte proliferation and psoriatic-like inflammatory responses provide a new treatment plan for psoriasis with potential therapeutic effects.
Smart Images

Figure CN118948839A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of verteporfin in preparing a drug for treating psoriasis. Background Art
[0002] Psoriasis, also known as psoriasis, is a chronic inflammatory skin disease that is prone to relapse. Its main pathophysiological characteristics are reflected in abnormal proliferation of keratinocytes, prominent dilation of dermal blood vessels, and infiltration of inflammatory cells. The clinical symptoms are mainly manifested as erythema and scaling caused by excessive proliferation and differentiation of stratum corneum cells, as well as severe skin inflammation, which have varying degrees of impact on the patient's physiology, psychology, daily activities, and family life. In addition, psoriasis has a long course of disease, is very prone to relapse, and is particularly difficult to cure. There is currently no better treatment method. Based on this, it is hoped that a new treatment plan for psoriasis can be developed.
[0003] Verteporfin (VP, Verteporfin), chemical name is 9-methyl (I) and 13-methyl (II) trans-(±)-18-ethylene-4,4a-dihydro-3,4-bis (methyl ester)-4a,8,14,19-tetramethyl-23H,25H-benzoporphyrin-9,13-dipropyl ester (such as Figure 1 Verteporfin is a YAP inhibitor that can disrupt the YAP-TEAD interaction and is also a photosensitizer used in photodynamic therapy. It is often used to eliminate abnormal intraocular blood vessels associated with diseases such as age-related macular degeneration, and to treat pathological myopia or suspected ocular histoplasmosis. There is no record of using verteporfin to treat psoriasis in the prior art. Summary of the invention
[0004] The purpose of the present invention is to provide a new solution for treating psoriasis.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides application of verteporfin and pharmaceutically acceptable salts thereof in preparing a drug for treating psoriasis.
[0007] Preferably, when the verteporfin is used as a drug for treating psoriasis, it is manifested in that verteporfin inhibits the proliferation of keratinocytes, and has an inhibitory effect on psoriasis-related inflammatory factors CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1β, and has an inhibitory effect on the phosphorylation of STAT3 and NF-κB.
[0008] The present invention proves through experiments that verteporfin treatment can significantly inhibit the proliferation of keratinocytes, and has an inhibitory effect on psoriasis-related inflammatory factors CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1β, and has an inhibitory effect on the phosphorylation of STAT3 and NF-κB. In general, verteporfin can simultaneously inhibit keratinocyte proliferation and psoriasis-like inflammatory reactions, and can be used to prepare drugs for treating psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 This is the structure diagram of verteporfin.
[0010] Figure 2 Representative images of the changes in the cell number of HaCaT keratinocytes treated with different concentrations of verteporfin in Example 1 (scale bar: 50 μm).
[0011] Figure 3 The relative proliferation rate of HaCaT cells treated with different concentrations of verteporfin in Example 1 (n=3).
[0012] Figure 4 The cell cycle flow cytometry results of HaCaT keratinocytes treated with verteporfin in Example 1.
[0013] Figure 5 The ratios of cells in different cell cycles in Example 1 (n=3), compared with the control group, **: P<0.01, *: P<0.05.
[0014] Figure 6 The mRNA expression levels of psoriasis-related inflammatory genes in HaCaT keratinocytes treated with different concentrations of verteporfin with or without M5 treatment in Example 2 (n=4). Compared with the control group, ###: P<0.001, ##: P<0.01, ***: P<0.001, **: P<0.01, *: P<0.05.
[0015] Figure 7 The protein expression levels of psoriasis-related inflammatory signaling pathways in HaCaT keratinocytes treated with different concentrations of verteporfin in the presence or absence of M5 treatment in Example 2. DETAILED DESCRIPTION
[0016] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0017] Example 1
[0018] The effects of different concentrations of verteporfin (VP, 5μM / 10μM) on the proliferation and cell cycle of HaCaT keratinocytes were investigated.
[0019] HaCaT cells were counted and 10 cells were placed in each well. 5 cells (total volume of cell suspension is 2 mL / well) were inoculated into 6-well plates, and when the cell density reached about 70%, different concentrations of verteporfin (the group with a final concentration of 5 μM verteporfin can be called VP 5 μM group, and the group with a final concentration of 10 μM verteporfin can be called VP 10 μM group) and the same volume of DMSO were added to the cell culture medium as a control (CTL group). After 24 hours of treatment, cell pictures were randomly taken by a microscope camera to observe the effects of different concentrations of verteporfin on the density of HaCaT keratinocytes as a whole;
[0020] The CCK8 assay was used to detect the effects of different concentrations of verteporfin (VP) on keratinocyte proliferation;
[0021] Flow cytometry was used to detect the effects of different concentrations of verteporfin (VP) on the cell cycle of keratinocytes.
[0022] Microscopic observation of cells and CCK8 experiments revealed that compared with the control group, the number of cells in the verteporfin-treated group was significantly reduced, and proliferation was significantly inhibited in a dose-dependent manner ( Figure 2 and Figure 3 At the same time, cell cycle detection revealed that compared with the control group, the cells in the treatment group were blocked in the G0 / G1 phase of the cell cycle ( Figure 4 and Figure 5 ), further demonstrating that verteporfin treatment significantly inhibited keratinocyte proliferation.
[0023] Example 2
[0024] To investigate the effects of different concentrations of verteporfin on psoriasis-like inflammation of HaCaT keratinocytes.
[0025] HaCaT cells were counted and inoculated into 6-well plates. When the cell density reached about 40%, M5 (final concentration of 10 ng / mL) (IL-17, IL-1α, TNF-α, IL-22 and OSM were all purchased from PeproTech, with final concentrations of 10 ng / mL, and mixed thoroughly) was added to the cell culture medium as the M5-treated group, and the same volume of PBS was used as the control for treatment as the CTL group, i.e., the group not treated with M5. The cell density of the two experimental groups was about 70% after 24 hours of induction. Then, three concentrations of verteporfin (VP) of 0 μM, 5 μM, and 10 μM were used to treat the two groups of cells respectively. After 24 hours of treatment, Realtime PCR and Western Blots were used to detect the effects of different concentrations of verteporfin (VP) on the expression of psoriasis-related inflammatory genes (including CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1β) in keratinocytes and related inflammatory signaling pathways (including STAT3 and NF-κB).
[0026] like Figure 6 As shown in the figure, by comparing the data of the M5 VP 0μM group and the CTLVP 0μM group, it was found that the expression of psoriasis-related inflammatory factors in keratinocytes, such as CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1β, was significantly upregulated after M5 treatment of keratinocytes, proving that M5 induces keratinocytes to produce a psoriasis-like inflammatory state. Comparing the data of the two groups (i.e., the M5-treated group and the group not treated with M5), i.e., the effects of different concentrations of verteporfin on psoriasis-related inflammatory genes in keratinocytes, it was found that verteporfin could significantly reduce the expression of relevant inflammatory factors in psoriasis with or without M5 induction.
[0027] like Figure 7 As shown in Figure 2, verteporfin significantly inhibited STAT3 (p-STAT3) in the presence or absence of M5 induction. Tyr705 and p-STAT3 Ser727 ) and NF-κB (NF-κB Ser311 ) phosphorylation, indicating that verteporfin can significantly inhibit the activation of psoriasis-related inflammatory pathways (including STAT3 and NF-κB). Therefore, verteporfin can inhibit psoriasis-like inflammatory responses in keratinocytes.
[0028] In summary, verteporfin can simultaneously inhibit keratinocyte proliferation and psoriasis-like inflammatory response, and has application potential in the preparation of drugs for the treatment of psoriasis.
[0029] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of verteporfin and its pharmaceutically acceptable salts in the preparation of drugs for treating psoriasis.
2. The use according to claim 1, characterized in that: When verteporfin is used as a drug for treating psoriasis, it is manifested in that verteporfin inhibits the proliferation of keratinocytes, and has an inhibitory effect on psoriasis-related inflammatory factors CXCL1 / CXCL2 / CXCL8, CCL2 / CCL20 and IL-1β, and has an inhibitory effect on the phosphorylation of STAT3 and NF-κB.
Citation Information
Patent Citations
Application of isoferulic acid in preparation of medicine for treating psoriasis
CN117462524A
Application of kushenol F in preparation of medicine for treating psoriasis
CN117815220A
